4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-167091
Chief Development Officer sold 20,225 shares at $39.99 ($808,844)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yeleswaram Krishnaswamy Chief Development Officer | 2026-04-17 | Sale 10b5-1 | −20,225 | $39.99 | $808,844 | 246,426 | D |
| Open-market sales · 20,225 sh · avg $39.99 · $808,844 | |||||||
Loading xslF345X06/ownership.xml…